{"id":301,"date":"2026-01-05T09:30:27","date_gmt":"2026-01-05T09:30:27","guid":{"rendered":"https:\/\/non-igg-ab.creative-biolabs.com\/blog\/?p=301"},"modified":"2026-01-06T05:57:35","modified_gmt":"2026-01-06T05:57:35","slug":"developability-non-igg-aggregation-heterogeneity-stability","status":"publish","type":"post","link":"https:\/\/non-igg-ab.creative-biolabs.com\/blog\/developability-non-igg-aggregation-heterogeneity-stability\/","title":{"rendered":"Developability for Non-IgG: Aggregation, Heterogeneity, and Stability"},"content":{"rendered":"

Non-IgG antibodies\u2014especially IgA, IgM, and IgE<\/strong>\u2014are re-entering biologics pipelines for reasons IgG cannot always match: mucosal targeting, high avidity through multivalency, and specialized effector biology. But the same structural features that make these isotypes exciting also make them harder to manufacture, characterize, and stabilize<\/strong>. In practice, many non-IgG programs don\u2019t fail on target engagement; they fail when the molecule meets real-world CMC constraints: aggregation<\/strong>, product heterogeneity<\/strong>, and stability loss<\/strong> during expression, purification, fill\u2013finish, or storage.<\/p>\n

This article breaks down why<\/em> these three developability risks show up early in non-IgG projects, what \u201cgood\u201d looks like for controlling them, and how to build a decision-ready developability strategy before you commit to expensive scale-up.<\/p>\n

\"\"<\/p>\n

\n

Why Non-IgG Developability Is a Different Game<\/h2>\n

With IgG, the industry has decades of playbooks: established expression systems, platform purification, and familiar analytical comparability expectations. Non-IgG formats add layers of complexity that directly increase the probability of early CMC derailment:<\/p>\n

    \n
  • \n

    Higher-order assembly and valency<\/strong>
    IgM commonly forms pentamers (often with a J chain) or hexamers; IgA can be monomeric or polymeric; these assemblies introduce more interfaces where mispairing and aggregation can occur.<\/p>\n<\/li>\n

  • \n

    Heavier and more diverse glycosylation<\/strong>
    Non-IgGs can carry more N-glycans (and, in some contexts, additional O-glycosylation), expanding the heterogeneity space and altering thermal\/colloidal behavior.<\/p>\n<\/li>\n

  • \n

    More disulfide and domain architecture variability<\/strong>
    Additional interchain linkages, alternative tailpieces, and isotype-specific constant-region features can create sensitivity to redox conditions, pH shifts, and shear.<\/p>\n<\/li>\n

  • \n

    Less \u201cplatform\u201d process compatibility<\/strong>
    Even if the binding domain behaves nicely, the isotype scaffold may require custom expression tuning<\/strong>, non-standard purification logic<\/strong>, and a more deliberate formulation strategy<\/strong>.<\/p>\n<\/li>\n<\/ul>\n

    The implication is simple: developability must be treated as a front-loaded design variable<\/strong>, not a downstream QC checkbox.<\/p>\n

    \n

    Aggregation: The First (and Loudest) Signal of Trouble<\/h2>\n

    Aggregation is often the earliest visible symptom of a non-IgG developability problem because it can be triggered by multiple stressors\u2014temperature excursions, concentration increases, pH transitions, freeze\u2013thaw cycles, mixing, filtration, and even routine hold steps.<\/p>\n

    What makes non-IgGs aggregation-prone?<\/h3>\n

    Aggregation risk tends to rise when a molecule has (1) more interaction surfaces and (2) more opportunities for partial unfolding:<\/p>\n